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Aim. To describe the retention rates for biological therapies in patients with rheumatoid arthritis (RA), psoriatic arthritis (PsA),
and ankylosing spondylitis (AS) in a clinical setting. Methods. All patients managed in a dedicated biological therapy clinic in a
teaching hospital in Australia were assessed for continuation on biological treatments and reasons for switching to an alternative
biological agent or cessation of treatment. Results. There was a lower retention rate for RA patients on biological therapies
compared to PsA and AS patients and the retention rate for RA patients was lower than that reported in RCTs. Conclusions. The
retention rate on biological therapies for RA patients was lower in the clinic setting than what is reported in RCTs. The reasons for
the lower retention rate in the clinical setting are discussed but no clear determinants for nonresponse to biological agents were
identiﬁable. These agents have very limited steroid sparing eﬀects.
Copyright © 2009 J. Ninan et al.ThisisanopenaccessarticledistributedundertheCreativeCommonsAttributionLicense,which
permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
1.Introduction
The treatment of inﬂammatory joint diseases (rheumatoid
arthritis (RA), psoriatic arthritis (PsA), and ankylosing
spondylitis (AS)) has been revolutionised with the introduc-
tion of biological therapies.
Biologic Therapy refers to treatment that boosts or
restores the ability of the immune system to ﬁght inﬂamma-
tory arthritis, cancer, and other diseases.
The major biologic approaches in clinical use include
agents that interfere with cytokine function and those that
inhibit the “second signal” required for T cell activation as
well as agents that deplete B cells.
Randomised clinical trials (RCTs) have demonstrated a
remarkable consistency in clinical responses to all biological
agents (Inﬂiximab, Etanercept, Adalimumab, Rituximab,
Abatacept, and Tocilizumab) with all agents producing
ACR20, ACR50, and ACR70 responses around 60%, 40%,
and 20%, respectively, at 1 year followup for RA patients [1–
6]. The duration of these RCTs have varied between 52 weeks
and 4 years [1, 3].
The retention rate for RA patients on biological agents is
also high, varying from 57 to 88% in RCTs although at least
one study [7, 8] has suggested that the retention rate is much
lowerinanontrialsetting,fallingtoaslowas39%threeyears
after commencement of a biological agent.
Coprescription of a disease modifying agent (DMARD),
which is usually Methotrexate, seems to increase the clinical
eﬃcacy of and retention rates for biological therapies in RA
[9–11] and the retention rates appear to be higher in the PsA
and AS patient groups compared to the RA patient group [7,
8, 12, 13].
It has been noted that there is a selection bias in the
inclusion of patients in RCTs of biological treatments with
many patients who are treated in the “real world” not
meeting the inclusion criteria for RCTs [14, 15]. The clinical
response to and the retention rates on biological treatments
appear to be signiﬁcantly lower in those patients who do
not meet the inclusion criteria for RCTs compared to those
of patients who do meet these inclusion criteria. It has
also been suggested that the RA patients treated in the
“real world” have less disease activity when commencing
biological agents and that this may explain the lower eﬃcacy
inthispatientgroup[8].However,otherstudiesreportmuch
higher retention and eﬃcacy rates in RA patients receiving
treatment with TNF blockers [12, 16, 17].
Most RA patients included in RCTs are taking oral cor-
ticosteroids and it is not clear how eﬀective treatment with2 International Journal of Rheumatology
biological agents is in allowing a reduction in or cessation of
oral corticosteroid treatment [18–20].
The cost of biological treatment is subsidised by the
Australian Government so access to biological treatments
for RA, PsA, and AS is not limited by individual ﬁnancial
constraints. However, there are restrictions in access to
biological treatments imposed by the government with RA
and PsA patients requiring to have a minimum of 20 tender
and swollen joints (or four major joints including elbows,
wrists, ankles, and knees) along with a CRP > 15mg/L
and/or an ESR > 25mm/hour. RA and PsA patients must
demonstrate a 50% reduction in tender and swollen joints
and a 20% reduction in ESR or CRP levels at 3 months and
continue to demonstrate such a response every 6 months
in order to continue on biological treatment. AS patients
must demonstrate a BASDAI (Bath Ankylosing Spondylitis
Disease Activity Index) > 4.0 with a CRP > 10mg/L and/or
an ESR of > 25mm/hour and demonstrate a 50% reduction
in BASDAI and a 20% reduction in ESR or CRP levels at 3
months to continue on biological treatments. This response
must be continued at assessments done every 6 months to
continue on biological treatments. Biological treatments are
given at ﬁxed doses and treatment intervals as deﬁned by
RCTs and there is no provision for altering the dose or
frequencyoftreatmentsintheeventoflossofclinicaleﬃcacy.
Therefore, if patients do not meet the pre-deﬁned response
criteria, they are recorded as a treatment failure (either
primaryorsecondary)andmustbeswitchedtoanalternative
biological therapy. Primary treatment failed was deﬁned as
the patient not demonstrating eﬃcacy with treatment at any
time while secondary treatment failure was deﬁned as an
initial demonstration of response to treatment which was
subsequently lost on continued treatment with a biological
agent.
This paper presents the results of a retrospective study
of clinical outcomes and retention rates for all patients (RA,
PsA, and AS) commenced on biological agents since the
commencement of a dedicated biological therapy clinic at a
teaching hospital in 2002.
2. Methods
A dedicated clinic in a major teaching hospital in Adelaide,
South Australia, was established in 2002 to treat initially
RA and then PsA and AS patients with biological therapies.
This clinic drains patients from the Southern region of
Adelaide, a city of 1.2 million people, with an estimated
drainage population of 400000 people. All patients are
assessedandfollowedupexclusivelyinthisclinic.Allpatients
from the clinic who had received biologic therapies as
of June 30 2008 were included in the study. Data was
collected from medical records and Medicare application
forms by the investigators and entered into a computerised
database. Data collection included joint counts, patient
global response, modiﬁed Health Assessment Questionnaire
(HAQ), laboratory (Rheumatoid Factor (RF), anticyclic
citrullinated peptide (anti-CCP), C reactive protein (CRP)
and erythrocyte sedimentation rate (ESR)) and radiological
outcomes for RA patients; joint counts, patient global
response,ESRandCRPforPsApatientsandBathAnkylosing
Spondylitis Disease Activity Index (BASDAI), ESR and CRP
forASpatients.Asthiswasprimarilyaclinicalauditanethics
approval was not sought.
Primary treatment failed was deﬁned as the patient not
demonstrating eﬃcacy with treatment at any time while
secondary treatment failure was deﬁned as an initial demon-
strationofresponsetotreatmentwhichwassubsequentlylost
on continued treatment with a biological agent.
2.1. Statistical Analysis. Statistical analysis was done using
ChiSquaretests,KaplanMeiersurvivalstudiesusingEPIinfo
software.
3. Results
One hundred and forty patients with RA, PsA, or AS
were treated with biological agents as of 30 June 2008
(Table 1). In the RA group (93), ﬁrst biological agent oﬀered
was Etanercept (52), Adalimumab (35), Inﬂiximab (5), or
Anakinra (1). Forty one patients (44.1%) ceased the ﬁrst
biological agent commenced, with 29 of the 41 (70.7%)
c easingbecauseoflackofeﬃcacy(8primaryeﬃcacyfailures,
21 secondary eﬃcacy failures). Twelve (29.3%) of patients
ceased treatment due to side eﬀects including signiﬁcant
skin rashes including injection site reactions, exacerbation
of heart failure, and serious infections. Thus the initial
retention rate for the ﬁrst biologic agent was 55.9%.
The median duration of treatment with the ﬁrst biologic
agent was 17 months: Adalimumab 16, Etanercept 17,
Inﬂiximab10, Anakinra 23.
In the RA group 47 (50.5%) were taking Methotrexate,
Leﬂunamide (5), Hydroxychloroquine (3), and Salazopyrin
(4) as cotherapy. Also of note was that 50.5% of the RA
patients continued to require low dose prednislone (mean
dose7.9mg ±4.8mg)at9monthsfordiseasecontroldespite
attempts to slowly withdraw them from corticosteroid
treatment.
39 of the 41 patients who failed ﬁrst biological went on
to a second agent. 18 (46.2%) of these continued to show
an ACR50 response. There were 5 primary failures and 7
secondary failures in this group. Nine patients developed
side eﬀects to the second biologic agent. Median duration of
treatment with the second biologic agent was 16.5 months,
18 months (Adalimumab), 26(Etanercept), 7(Inﬂiximab).
The retention rate with the second biologic was 47.4%
in those who were taking an additional DMARD usually
Methotrexate compared to 45% in those not on any addi-
tional DMARD (P = .74).
19 of the 21 patients who failed the second biologic
agent went on to a third agent including Rituximab(6) and
Abatacept(5) of these 14 continue to respond, there was 1
secondary failure and 2 primary failure and 2 developed side
eﬀects.
Within the RA patient group, we were unable to identify
any determinants of treatment failure as the numbers were
small to perform additional analyses. Males had a slightly
better chance of responding to the ﬁrst biological therapy
than females 58.3% versus 56.5% (P = .22) chi square 4.3,International Journal of Rheumatology 3
Table 1: Baseline demographic and clinical characteristics.
Diagnosis RA (n = 93) PsA (n = 27) AS (n = 20)
Mean age (years ± sd) 62.35 (±12.4) 51.7 (±12.5) 48.8 (±9.2)
Sex (m : f) 24 : 69 15 : 12 15 : 5
Mean duration of illness (years ± sd) 14.7 (±10.3) 12.6 (±8.9) 12.6 (±11.3)
Tender and swollen joint count or BASDAI (AS patients) 25.9 (±7.4) 25.7 (±8.9) 7.8 (±1.59)
Mean CRP (mg/L) 43.5 (±39.1) 58.8 (±59.1) 47.1 (±44.0)
Mean ESR (mm/hr) 46.9 (±26.1) 36.8 (±18.6) 38.8 (±20.1)
% use of Corticosteroids 50.5 12 5
% use of Methotrexate 50.5 38.5 20
% chronic pain, Fibromyalgia 16.7% 15.8% 7.1%
sd: standard deviation, BASDAI: Bath Ankylosing Spondylitis Disease Activity Index, RA: Rheumatoid Arthritis, PsA: Psoriatic Arthritis, AS: Ankylosing
Spondylitis, CRP: C Reactive Protein, ESR: Erythrocyte Sedimentation Rate.
but there was no diﬀerence in the age or disease duration
between the responders and nonresponders to the ﬁrst
biological agent used.
Disease activity, including mean CRP levels, was similar
between the responders and nonresponders while there was
actually a higher level of Methotrexate cotherapy in the
nonresponders group (57%) compared to the responders
(52%) although this was probably by chance (P = .58).
3.1. Psoriatic Arthritis (27). Twenty seven patients with
Psoriatic arthritis were treated with biologic agents 13(Etan-
ercept), 6(Adalimumab), 8(Inﬂiximab)
The results were markedly diﬀerent in this patient group
compared to the RA group with only 9 patients ceasing
the original biological agent: 1 primary treatment failure,
1 secondary treatment failure, 4 because of side eﬀects
(exacerbation of skin disease and infections), and 3 for other
reasons including preference to a subcutaneous injection as
opposed to infusion suggesting a response rate of 92.6% and
retention rate of 66% to the ﬁrst biologic agent (Figure 1).
These patients who discontinued the ﬁrst agent were
treated with a second agent. 7 of these patients continued to
maintain good response. 1 failed and 1 developed side eﬀects
to the second agent. Both these patients are doing well on a
third agent.
Only 12% of patients continued to take low dose corti-
costeroids.
3.2. Ankylosing Spondylitis (20). In the AS patient group,
all patients remained on biological therapies with 16 (80%)
continuing on the original biological agent prescribed. Two
of the patients switched to a diﬀerent biological therapy
because of side eﬀects and two switched due to primary
treatment failure.
4. Discussion
We describe in this paper our results of treatment with
biological agents for RA, PsA, and AS from a single rheuma-
tology unit in the setting of a dedicated biological therapy
clinic.OurresultsaresimilartothoseofDuclosetal.[7]with
a higher retention rate on biological therapies in AS and PsA
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Figure 1: Kaplan-Meier survival curves for ﬁrst biologic agent
according to diagnosis P-value .0082.
patients compared to RA patients. We have also showed that
primary and secondary treatment failures result in around a
third of patients failing to continue with treatment with the
ﬁrst and second biological therapy while retention rates were
higher with the third biological treatment, although patient
numbersinthisgrouparelow.Therewashoweveratendency
towardsimprovementinHAQscoresalthoughthiscouldnot
be analysed separately because of incomplete data.
These results are not as good as those seen in RCTs
of biological therapies in RA. The reasons for the poorer
response to biological therapies outside of RCTs are not
clear but it has been suggested that selection bias, disease
activity, patient choice or expense could all explain some of
the diﬀerences seen [8]. It has also been suggested that the
rigorous inclusion criteria for RCTs are not met by many
of the patients who receive biological therapies in the clinic
setting [14, 15] with the clinical response being suboptimal4 International Journal of Rheumatology
in those patients who did not meet RCT inclusion criteria
[15]. The average age of the patients in this study was higher
than that in RCTs as were the number of comorbidities but
that is to be expected in the real world.
In our study, we have not found any determinants
which predicted nonresponders to biological therapies,
including disease activity, coprescription of DMARDs, age,
sex, or disease duration. It is possible that the stringent
requirements that the Australian government has imposed
for subsidisation of biological therapies may have had an
eﬀect on the biological therapy retention rate in our study,
particularly as patients have to approach an ACR50 response
to continue to receive subsidised treatment with biological
therapies in Australia. However, another study of biological
therapy in RA in Australia using only Etanercept has shown
that 88% of patients remained on therapy with Etanercept
at 12 months [21]. In addition, PsA patients have to meet
similar response criteria to RA patients in order to receive
subsidised biological treatment in Australia, yet we had
a 92.6% response rate and a 66% retention rate to the
ﬁrst biological agent used in the PsA group in this study
compared to 56% retention rate in RA (P = .008). Retention
rates fall for subsequent TNF blockers from 56% to 46%
and although there is some justiﬁcation for switching agents
one will eventually run out of agents with this trend. A
recent report on outcomes of TNF blocker treatment in
the South Swedish Arthritis Treatment Group Register has
demonstrated similar results to our outcomes in this study
with 26% of patients switching to a second TNF blocker
with a 51% ACR20 and a 27% ACR50 response and a 13%
switch to a third TNF blocker with a 35% ACR20 and a 18%
ACR50 response [22]. This suggests that patients who fail to
respond to the ﬁrst TNF blocker are unlikely to do well on
subsequent TNF blockers and consideration should be given
to use an alternative biological agent, Abatacept, Rituximab,
or Tocilizumab.
It is possible that the inability to escalate dose or
reduce the time between biological agent treatments in
Australia could have resulted in the lower retention rate
seen in this study. There is some evidence that treatment
with Inﬂiximab does demonstrate acquired drug resistance
with a requirement for dose escalation over time [23], but
this is unlikely to have aﬀected our results signiﬁcantly
as the predominant biological therapies used in the RA
group were Etanercept and Adalimumab. A recent trial has
not demonstrated any beneﬁt from dose escalation with
Etanercept treatment [24].
We also demonstrated that over half the RA patients in
this study were unable to come oﬀ corticosteroids, despite
repeated eﬀorts to slowly wean patients oﬀ corticosteroids
while they were receiving treatment with a biological agent.
Most of the RCTs do not measure withdrawal of corticos-
teroids as an endpoint in the studies so there is limited
evidence that the use of biological agents in the treatment
of RA has a corticosteroid sparing eﬀect [18–20]. There are a
number of potential reasons for why RA patients, more than
P s Ap a t i e n t s ,a r eu n a b l et or e d u c et h eu s eo fc o r t i c o s t e r o i d s ,
including the perception that biological therapies are not as
eﬀectiveintheRAgroupastheyareinthePsApatientgroup.
Although this study has some limitations because of its
retrospective observational design we believe it adds to our
existing knowledge of biologic agent success and failures in
the real world.
5. Summary
In summary, we have demonstrated in our clinic setting that
the response to biologic therapies is greater in the PsA and
AS group of patients than in RA patients and there is a lower
retention rate on these agents in the RA group compared to
whatisseeninRCTs.Thereasonsforthislowerretentionrate
are not readily apparent in this study.
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